A Study to Evaluate the Efficacy and Safety of Adjunctive Troriluzole in Obsessive-Compulsive Disorder

Source: ClinicalTrials.gov results for NCT04693351 (opens in a new tab)· Licence: public-domain

First posted 22 May 2026 · Last update posted 22 May 2026 · Imported 26 Oct 2026 from ClinicalTrials.gov download 2026-10-25

Primary outcomes with a statistical analysis

1. Change From Baseline in the Y-BOCS Total Score in the Baseline Y-BOCS ≥24 Stratification Cohort at Week 8 (Negative Change Indicates Symptom Improvement)

   Time frame

   Baseline and Week 8

   Measure

   Least squares mean

   Unit

   score on a scale

   • Troriluzole vs PlaceboSuperiority

     Model-based summary statistics are from a mixed model with repeated measures, including fixed effects for treatment, geographic region, current SOC Medication stratification, visit, treatment-by-visit interaction, baseline score, baseline score-by-visit interaction as covariates and participant as random effect. An unstructured covariance matrix with degrees of freedom using Kenward-Roger approximation was used.

     Estimate

     0.97Least squares mean difference

     95% CI, two-sided

     0.02 to 1.92

     p-value

     0.041

     Method

     Mixed Models Analysis

Serious adverse events

Time frame: For Adverse Events: From first dose up to approximately 12 weeks For All-cause Mortality: From Day 1 up to approximately 12 weeks

Posted results as ClinicalTrials.gov prints them: primary outcome analyses and serious adverse event totals only. Registry facts, not reviewed by HealthTrade and not investment advice; filing-derived results are listed separately.

Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.